
Novo CEO Charts Course to Rethink Obesity Drug Strategy
Novo Nordisk's CEO Mike Doustdar is implementing sweeping changes to the company's culture and strategy. The rebranding effort signals a broader reset in how the drugmaker approaches its high-profile obesity treatment business.
September 19, 2026




































